Narcolepsy Therapeutics Market is segmented By Disease Type (Daytime Extreme Sleepiness, Cataplexy, Others), By Therapeutic Type (Sodium Oxybate, Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Narcolepsy Therapeutics Market Size
The Global Narcolepsy Therapeutics Market reached USD 2.8 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 5.9 billion by 2031. The narcolepsy therapeutics market is expected to exhibit a CAGR of 9.7% during the forecast period (2024-2031). The narcolepsy therapeutics market is a growing sector within the pharmaceutical industry, driven by factors such as increasing prevalence and rising awareness.
Key medications for narcolepsy include stimulants, selective serotonin reuptake inhibitors (SSRIs), sodium oxybate, and tricyclic antidepressants. Research and development efforts are focused on identifying new therapeutic targets and treatment approaches.
The narcolepsy therapeutics market is driven by factors such as the increasing prevalence of narcolepsy, increasing research and development activities on narcolepsy therapeutics, increasing awareness about various treatment options, rising stress levels, technological advancements in therapeutics, and advancements in diagnostic techniques.
Narcolepsy Therapeutics Market Summary
|
Metrics |
Details |
|
CAGR |
9.7% |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
By Disease Type, By Therapeutic Type |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more insights - Request Free Sample
Narcolepsy Therapeutics Market Dynamics
Increasing Research and Development Activities
The increasing research and development activities on narcolepsy therapeutics are a major factor expected to increase the market. Pharmaceutical companies and research institutions are actively engaged in developing new therapeutic options for narcolepsy. Ongoing research and development activities contribute to market growth by introducing innovative treatment approaches.
Research and development endeavors strive to achieve personalized medicine for narcolepsy patients. By identifying genetic markers or biomarkers associated with the disorder, researchers can tailor treatment strategies to individual patients, leading to more targeted and effective therapies.
For instance, in March 2023, the European Medicines Agency has just granted an extension of the indication for the marketing authorization for WAKIX (pitolisant), which is now indicated for the treatment of narcolepsy in children from the age of 6 years, with or without cataplexy.
Increasing Awareness About Various Treatment Options
There is a growing awareness among healthcare professionals and the general public about narcolepsy as a distinct neurological disorder. Awareness campaigns educate patients about the different available treatment options for narcolepsy. By understanding the range of choices, patients can actively participate in shared decision-making with healthcare professionals and make informed decisions regarding their treatment.
Increased awareness helps individuals recognize the symptoms of narcolepsy and seek medical attention promptly. Early diagnosis and timely initiation of treatment can lead to better management of symptoms and improved long-term outcomes.
For instance, in March 2023, Jazz Pharmaceuticals plc announced an expansion of its support of the American Heart Association to provide the sleep disorder community with an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients they treat.
High Cost of Treatment
The high cost of narcolepsy treatment is a major factor expected to hinder market growth. Some narcolepsy medications, particularly newer and innovative therapies, can be expensive. The high cost of treatment limit access for certain patients, especially in regions with limited healthcare coverage or affordability.
The cost of medications used in the treatment of narcolepsy can be substantial. Certain medications, such as sodium oxybate, can be particularly expensive. Patients are unable to take these medications on a long-term basis due to the unaffordable cost, leading to hampering the market growth of narcolepsy therapeutics.
Narcolepsy Therapeutics Market Segment Analysis
The global narcolepsy therapeutics market is segmented based on disease type, therapeutic type, and region.
Based On Therapeutic Type, the Central Nervous System Stimulants Segment is Expected to Dominate the Market Share
Based on the therapeutic type, the central nervous system stimulants segment is expected to dominate the market share during the forecast period. The market for central nervous system stimulants holds 29.1% of the market share in 2022. CNS stimulants, such as modafinil and armodafinil, have demonstrated efficacy in reducing excessive daytime sleepiness, which is one of the primary symptoms of narcolepsy.
These medications promote wakefulness and help patients stay alert during the day, improving their ability to carry out daily activities. Despite the dominance of CNS stimulants, ongoing research and development efforts are focused on developing newer and more effective drugs in this therapeutic category. This continuous innovation helps maintain the dominance of CNS stimulants while also driving advancements in narcolepsy treatment as a whole.
Source: DataM Intelligence Analysis (2023)
Narcolepsy Therapeutics Market Geographical Share
North America Holds the Largest Market Share Due to the Increased Awareness and Favorable Reimbursement Policies
The region holds the 38.7% market share for the narcolepsy therapeutics market in 2022 due to the increased awareness and favorable reimbursement policies in the region. North America, particularly the United States, has seen a rise in awareness about narcolepsy among healthcare professionals and the general population. This has led to improved diagnosis rates and increased demand for narcolepsy treatments, driving market growth.
North America has advanced healthcare infrastructure, including sleep disorder centers and specialized clinics, that facilitate early diagnosis and comprehensive management of narcolepsy. This infrastructure supports the demand for narcolepsy therapeutics in the region. Moreover, the favorable reimbursement policies in the region are also a factor expected to increase the demand for narcolepsy therapeutics in the region.
Source: DataM Intelligence Analysis (2023)
Narcolepsy Therapeutics Market Key Players
The major global players include Jazz Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Avadel Pharmaceuticals Inc., Bioprojet, Graymark Healthcare, Ligand Pharmaceuticals Inc., Novartis AG, XWPharma Ltd., and Shionogi Inc.
COVID-19 Impact on Narcolepsy Therapeutics Market
The COVID-19 pandemic had significantly impacted the narcolepsy therapeutics market. Clinical trials for new narcolepsy therapeutics have been delayed or interrupted due to the pandemic. Restrictions on travel, social distancing measures, and prioritization of COVID-19-related research may have affected the progress of clinical trials.
Lockdowns, restrictions, and overwhelmed healthcare systems have hindered patients' access to healthcare services, including the diagnosis and treatment of narcolepsy. This have led to delayed or inadequate care.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war significantly impacted the narcolepsy therapeutics market. The conflict leads to disruptions in transportation routes or trade restrictions between Russia and Ukraine, it could potentially impact the supply chains of pharmaceutical companies involved in the production and distribution of narcolepsy therapeutics. This resulted in delays or shortages of medications in certain regions.
The conflict impacted the approval processes and market access for narcolepsy therapeutics. Regulatory harmonization and alignment may be affected, potentially impacting the introduction of new therapies or generic alternatives.
Key Developments
- In May 2023, Jazz Pharmaceuticals plc announced that seven abstracts featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 3-7, 2023. Presentations include four posters featuring real-world data on Xywav (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, for the treatment of narcolepsy patients with cataplexy and/or excessive daytime sleepiness (EDS) and adult patients with idiopathic hypersomnia.
- In January 2023, Hikma Pharmaceuticals PLC, a pharmaceutical company announced that it launched an authorized generic version of Jazz Pharmaceuticals' Xyrem (sodium oxybate) oral solution CIII in the US. Sodium Oxybate oral solution, 0.5 g/mL is a prescription medicine used to treat people with narcolepsy for symptoms of sudden onset of weak or paralyzed muscles (cataplexy) and excessive daytime sleepiness (EDS), the multinational pharmaceutical company noted.
Why Purchase the Report?
- To visualize the global narcolepsy therapeutics market segmentation based on disease type, therapeutic type, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of narcolepsy therapeutics market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global narcolepsy therapeutics market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
